Drugs / Carrimycin
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04413214 | Dec 2019 → Dec 2022 | oral cavity squamous cell carcinoma | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04672564 | Mar 2021 → Mar 2022 | COVID-19 | Shenyang Tonglian Group CO., Ltd | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04286503 | Feb 2020 → Feb 2021 | COVID-19 | Beijing YouAn Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05988177 | Aug 2023 → Aug 2026 overdue | hemophagocytic syndrome | Beijing Friendship Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carrimycin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05988177 ↗ |
| Known as | 4''-isovalerylspiramycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650385 ↗ |
| Route | Oral | “200mg of Carrimycin after meals every morning (po) for three weeks” NCT04413214 ↗ |